AI Could Reshape Clinical Trials--and the Business of Pharma

Welcome back to, TIME's new twice-weekly newsletter about AI. If you're reading this in your browser, why not subscribe to have the next one delivered straight to your inbox? We hear a lot about how AI is accelerating drug discovery. But the number of drugs approved by the FDA has remained constant through the AI revolution, at around 50 per year. "The biggest problem in bringing new medicine to patients hasn't been drug discovery for a long time," says Ben Liu, the founder and CEO of Formation Bio, an AI company working in the biotech space.